Identify Candidates for COVID-19 Monoclonal Antibodies
April 2021
Bamlanivimab/etesevimab will be the third monoclonal antibody option authorized to treat OUTpatients with COVID-19.
This combo joins bamlanivimab and casirivimab/imdevimab as another single-dose IV infusion. And more are in the works.
These "mabs" block SARS-CoV-2 from entering cells. Combo products may also limit treatment-emergent resistant viral variants.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote